Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Zacks Equity Research Aug 17, 2026 Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs Zacks Equity Research Aug 13, 2026 ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.